Tarsus Pharmaceuticals, Inc. TARS Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s change in accrued liabilities?
- Tarsus Pharmaceuticals, Inc. (TARS) reported change in accrued liabilities of -$9.25M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s change in accrued liabilities changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s change in accrued liabilities decreased by 57.0% year-over-year, from -$5.89M to -$9.25M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s change in accrued liabilities?
- Over 2 years (2021 to 2023), Tarsus Pharmaceuticals, Inc.'s change in accrued liabilities has grown at a 109.6% compound annual growth rate (CAGR), from $1.76M to $7.73M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.